Biotech and pharmaceutical stocks have come to the forefront due to the pandemic. ChemoCentryx (NASDAQ:CCXI) aims to provide therapies to combat cancer, autoimmune diseases, and inflammatory disorders, but is it a buy? Read more to find out.ChemoCentryx (CCXI) is a biopharmaceutical business that develops therapeutics and brings them to market. CCXI therapeutics are administered orally instead of through a patch, gel, injection, or another delivery method.
CCXI's overarching goal is to provide the masses with therapeutics that combat different types of cancer, autoimmune diseases, and inflammatory disorders. This is certainly a desirable aim, yet reaching it is not exactly easy. As medical industry insiders admit, it might take decades or even centuries to develop a cure for cancer.
Does CCXI belong in your portfolio? Let's take a look at the details of this biopharmaceutical stock to answer that question.